Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

Chronic Hepatitis C Viral Infection Clinical Trial

Official title:

Do Low HDL Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01159613
• Other study ID #: HDL + HCV
• Status: Completed
• Phase: N/A
• First received: July 8, 2010
• Last updated: July 8, 2010
• Start date: April 2008
• Est. completion date: January 2009

Study information

• Verified date: July 2010
• Source: Ziv Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.

Description:

Lipoproteins are closely connected to the process of hepatitis C virus (HCV) infection. Metabolic syndrome predicts negative treatment outcome in HCV infection.

Aim: to assess the association between lipids components of the metabolic syndrome and sustained viral response (SVR).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: January 2009
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Chronic HCV genotype 1 naive patients

Exclusion Criteria:

• Co infection with HBV, HIV, HDV

• Decompensated liver disease

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Chronic Hepatitis C Viral Infection
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic
• Infection
• Virus Diseases

Intervention

Other:
• Responders
Responders
• Non Responders
Non Responders

Locations

Country	Name	City	State
Israel	Ziv medical center liver unit	Safed, Israel

Sponsors (2)

Lead Sponsor	Collaborator
Ziv Hospital	Hillel Yafe MC Hadera

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	sustained viral response	achieving SVR	72 weeks	No